Dr. Jinzi J. Wu is Founder, Chairman and CEO of Ascletis which was founded in 2013. Ascletis is an innovative R&D driven biotech with three commercial products. Ascletis (1672.HK) became the first pre-revenue biotech listed on the Hong Kong Stock Exchange in 2018. Under his leadership, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Ascletis is committed to developing and commercializing innovative drugs in the areas of viral diseases, NASH/PBC, and cancer to address unmet medical needs both in China and globally.

Dr. Wu has more than 20-year experience in Big Pharma and biotech. Prior to founding Ascletis, he was Vice President at GSK R&D in USA. He also held Sr. Scientist to Vice President at various Big Pharma and biotech all over the world.